Results 91 to 100 of about 313,244 (194)

EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy

open access: yesAdvanced Science, Volume 12, Issue 36, September 25, 2025.
This review provides new perspectives on EGFR's activation, mutations, and their impact on tumor immunotherapy. It summarizes how EGFR is activated and the current EGFR targeting strategy, evaluates their clinical outcomes in combination with immunotherapy, highlighting differential responses in tumors with EGFR wild‐type and different mutants.
Yuanzhuo Gu   +7 more
wiley   +1 more source

Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs [PDF]

open access: yes, 2016
© 2016, Springer Science+Business Media Dordrecht.Objective: Myelin oligodendrocyte glycoprotein (MOG) is one of the major autoantigens in multiple sclerosis (MS), therefore selective depletion of autoreactive lymphocytes exposing MOG-specific B cell ...
Dronina M.   +14 more
core  

Optimization of the Refolding Process for Recombinant Anti-EGFR Immunotoxin Produced in the Escherichia coli

open access: yesMajallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Īlām, 2021
Introduction: Overexpression of the EGFR is associated with carcinogenesis, and it is observed in more than 70% of head and neck cancers. The expression of an immunotoxin against EGFR designed as an alternative to full antibody led to the production of ...
Bahman Akbari
doaj  

Antibody-Based Immunotoxins for the Treatment of Cancer

open access: yesAntibodies, 2012
Antibody-based immunotoxins comprise an important group in targeted cancer therapeutics. These chimeric proteins are a form of biological guided missiles that combine a targeting moiety with a potent effector molecule.
Nurit Becker, Itai Benhar
doaj   +1 more source

Abstracts

open access: yesMolecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

open access: yesHaematologica, 2013
We conducted a phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with relapsed, refractory myeloid leukemias.
Gautam Borthakur   +10 more
doaj   +1 more source

Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and E. coli Cell-Free Systems. [PDF]

open access: yesInt J Mol Sci, 2022
Krebs SK   +9 more
europepmc   +1 more source

Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice

open access: yes, 2022
S.305-314Pancreatic carcinoma is the fifth leading cause of: cancer-related deaths in North America and Europe. Major reasons for the high mortality rate include the inability to detect pancreatic cancer at an early stage, extensive local invasion, and ...
Huhn, M.   +10 more
core   +1 more source

Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs

open access: yes, 2020
© 2016, Springer Science+Business Media Dordrecht.Objective: Myelin oligodendrocyte glycoprotein (MOG) is one of the major autoantigens in multiple sclerosis (MS), therefore selective depletion of autoreactive lymphocytes exposing MOG-specific B cell ...
Dronina M.   +14 more
core  

CD25 targeted therapy of chemotherapy resistant leukemic stem cells using DR5 specific TRAIL peptide

open access: yesStem Cell Research, 2017
Chemotherapy resistant leukemic stem cells (LSCs) are being targeted as a modern therapeutic approach to prevent disease relapse. LSCs isolated from methotrexate resistant side population (SP) of leukemic cell lines HL60 and MOLT4 exhibited high levels ...
Jayaprakasam Madhumathi   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy